4D pharma plc (LON:DDDD), a pharmaceutical company leading the development of live biotherapeutics, has today announced that the Company has received clearance from the Medicines and..
4D pharma plc (LON:DDDD), a clinical stage biopharmaceutical company, pioneering the development of Live Biotherapeutic Products, today announced an agreement with a subsidiary of MSD (tradename..
4D pharma plc (LON:DDDD), a pharmaceutical company leading the development of live biotherapeutics, has today announced that data from the Company’s completed Phase Ib double-blind placebo-controlled..
4D pharma plc (LON:DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announced that the Company has submitted, and the Medicines and Healthcare products..
4D pharma plc (LON:DDDD), a pharmaceutical company leading the development of live biotherapeutics, has today announced that the Company has submitted, and the U.S. Food and..
4D pharma plc (LON:DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, provided today the following update in relation to the development of its..
4D pharma plc (LON:DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, announced today that it allotted 635,692 new ordinary shares on 23 August..
4D Pharma Plc (LON:DDDD) is pioneering the development of Live Biotherapeutic Products (LBPs) as medicines based on the function of the microbiome in health and disease...
Zeus Capital Healthcare Research Director Dr Gary Waanders caught up with DirectorsTalk for an exclusive interview to discuss live biotherapeutics, what’s driving the interest in this..
The new age of live-biotherapeutics is the topic of conversation when Dr Gary Waanders, Healthcare Research Director at Zeus Capital talks to DirectorsTalk. Gary explains what..
